Stability of arsenic species and insoluble arsenic in human urine

Yen Ching Chen, Chitra J. Amarasiriwardena, Yu Mei Hsueh, David C. Christiani

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Urinary arsenic species are important short-term biomarkers that have been used in epidemiological studies. However, the stability of solublearsenic species and the amount of arsenic lost during sample pretreatment remain unclear. The objective of this study is to evaluate the stability of soluble arsenic species in urine and aqueous standards, as well as to assess the amount of insoluble and soluble arsenic lost during pretreatment (centrifugation and filtration, respectively). High-performance liquid chromatogram inductively coupled plasma mass spectrometry was used to speciate arsenic species {Arsenite [As(III)], arsenate [As(V)], monomethylarsonic acid [MMA(V)], monomethylarsonous acid [MMA(III)], dimethylarsinic acid [DMA(V)], and arsenobetaine [AsB]} in aqueous standards and in urine samples. The arsenic levels in both freshly collected urine samples (pH = 5.5-7.0) and National Institute of Standards and Technology Standard Reference Material 2670 toxic elements in frozen-dried urine (pH 4.4) remained constant up to 6 months when stored at -20°C. In an aqueous solution mixed with 10 μg/liter of As(III), As(V), MMA, and DMA standards, and stored at 4°C, As(III) and As(V) were stable only up to 4 weeks, and MMA and DMA remained stable up to 4.5 months. The same phenomenon was observed for 100 μg/liter mixed aqueous standards. There was no significant loss of arsenic species in urine (<5%) when passed through a 0.45-μm filter. The amounts of insoluble arsenic in urine lost during centrifuge ranged from 1/2 to 1/17 of soluble arsenic. These findings indicated that the urinary matrix plays an important role in stabilizing arsenic species. Also, the loss of insoluble arsenic in urine during centrifuging results in underestimation of arsenic exposure, and may explain the lack of an association between arsenic exposure and the risk ofhealth outcomes reported in some epidemiological studies.

Original languageEnglish
Pages (from-to)1427-1433
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume11
Issue number11
Publication statusPublished - Nov 1 2002

Fingerprint

Arsenic
Urine
Cacodylic Acid
Poisons
Centrifugation
Epidemiologic Studies
Mass Spectrometry
Technology

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Chen, Y. C., Amarasiriwardena, C. J., Hsueh, Y. M., & Christiani, D. C. (2002). Stability of arsenic species and insoluble arsenic in human urine. Cancer Epidemiology Biomarkers and Prevention, 11(11), 1427-1433.

Stability of arsenic species and insoluble arsenic in human urine. / Chen, Yen Ching; Amarasiriwardena, Chitra J.; Hsueh, Yu Mei; Christiani, David C.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 11, No. 11, 01.11.2002, p. 1427-1433.

Research output: Contribution to journalArticle

Chen, YC, Amarasiriwardena, CJ, Hsueh, YM & Christiani, DC 2002, 'Stability of arsenic species and insoluble arsenic in human urine', Cancer Epidemiology Biomarkers and Prevention, vol. 11, no. 11, pp. 1427-1433.
Chen, Yen Ching ; Amarasiriwardena, Chitra J. ; Hsueh, Yu Mei ; Christiani, David C. / Stability of arsenic species and insoluble arsenic in human urine. In: Cancer Epidemiology Biomarkers and Prevention. 2002 ; Vol. 11, No. 11. pp. 1427-1433.
@article{9d56431b6fe54053b0a656cc8e8ce5f0,
title = "Stability of arsenic species and insoluble arsenic in human urine",
abstract = "Urinary arsenic species are important short-term biomarkers that have been used in epidemiological studies. However, the stability of solublearsenic species and the amount of arsenic lost during sample pretreatment remain unclear. The objective of this study is to evaluate the stability of soluble arsenic species in urine and aqueous standards, as well as to assess the amount of insoluble and soluble arsenic lost during pretreatment (centrifugation and filtration, respectively). High-performance liquid chromatogram inductively coupled plasma mass spectrometry was used to speciate arsenic species {Arsenite [As(III)], arsenate [As(V)], monomethylarsonic acid [MMA(V)], monomethylarsonous acid [MMA(III)], dimethylarsinic acid [DMA(V)], and arsenobetaine [AsB]} in aqueous standards and in urine samples. The arsenic levels in both freshly collected urine samples (pH = 5.5-7.0) and National Institute of Standards and Technology Standard Reference Material 2670 toxic elements in frozen-dried urine (pH 4.4) remained constant up to 6 months when stored at -20°C. In an aqueous solution mixed with 10 μg/liter of As(III), As(V), MMA, and DMA standards, and stored at 4°C, As(III) and As(V) were stable only up to 4 weeks, and MMA and DMA remained stable up to 4.5 months. The same phenomenon was observed for 100 μg/liter mixed aqueous standards. There was no significant loss of arsenic species in urine (<5{\%}) when passed through a 0.45-μm filter. The amounts of insoluble arsenic in urine lost during centrifuge ranged from 1/2 to 1/17 of soluble arsenic. These findings indicated that the urinary matrix plays an important role in stabilizing arsenic species. Also, the loss of insoluble arsenic in urine during centrifuging results in underestimation of arsenic exposure, and may explain the lack of an association between arsenic exposure and the risk ofhealth outcomes reported in some epidemiological studies.",
author = "Chen, {Yen Ching} and Amarasiriwardena, {Chitra J.} and Hsueh, {Yu Mei} and Christiani, {David C.}",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "11",
pages = "1427--1433",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Stability of arsenic species and insoluble arsenic in human urine

AU - Chen, Yen Ching

AU - Amarasiriwardena, Chitra J.

AU - Hsueh, Yu Mei

AU - Christiani, David C.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Urinary arsenic species are important short-term biomarkers that have been used in epidemiological studies. However, the stability of solublearsenic species and the amount of arsenic lost during sample pretreatment remain unclear. The objective of this study is to evaluate the stability of soluble arsenic species in urine and aqueous standards, as well as to assess the amount of insoluble and soluble arsenic lost during pretreatment (centrifugation and filtration, respectively). High-performance liquid chromatogram inductively coupled plasma mass spectrometry was used to speciate arsenic species {Arsenite [As(III)], arsenate [As(V)], monomethylarsonic acid [MMA(V)], monomethylarsonous acid [MMA(III)], dimethylarsinic acid [DMA(V)], and arsenobetaine [AsB]} in aqueous standards and in urine samples. The arsenic levels in both freshly collected urine samples (pH = 5.5-7.0) and National Institute of Standards and Technology Standard Reference Material 2670 toxic elements in frozen-dried urine (pH 4.4) remained constant up to 6 months when stored at -20°C. In an aqueous solution mixed with 10 μg/liter of As(III), As(V), MMA, and DMA standards, and stored at 4°C, As(III) and As(V) were stable only up to 4 weeks, and MMA and DMA remained stable up to 4.5 months. The same phenomenon was observed for 100 μg/liter mixed aqueous standards. There was no significant loss of arsenic species in urine (<5%) when passed through a 0.45-μm filter. The amounts of insoluble arsenic in urine lost during centrifuge ranged from 1/2 to 1/17 of soluble arsenic. These findings indicated that the urinary matrix plays an important role in stabilizing arsenic species. Also, the loss of insoluble arsenic in urine during centrifuging results in underestimation of arsenic exposure, and may explain the lack of an association between arsenic exposure and the risk ofhealth outcomes reported in some epidemiological studies.

AB - Urinary arsenic species are important short-term biomarkers that have been used in epidemiological studies. However, the stability of solublearsenic species and the amount of arsenic lost during sample pretreatment remain unclear. The objective of this study is to evaluate the stability of soluble arsenic species in urine and aqueous standards, as well as to assess the amount of insoluble and soluble arsenic lost during pretreatment (centrifugation and filtration, respectively). High-performance liquid chromatogram inductively coupled plasma mass spectrometry was used to speciate arsenic species {Arsenite [As(III)], arsenate [As(V)], monomethylarsonic acid [MMA(V)], monomethylarsonous acid [MMA(III)], dimethylarsinic acid [DMA(V)], and arsenobetaine [AsB]} in aqueous standards and in urine samples. The arsenic levels in both freshly collected urine samples (pH = 5.5-7.0) and National Institute of Standards and Technology Standard Reference Material 2670 toxic elements in frozen-dried urine (pH 4.4) remained constant up to 6 months when stored at -20°C. In an aqueous solution mixed with 10 μg/liter of As(III), As(V), MMA, and DMA standards, and stored at 4°C, As(III) and As(V) were stable only up to 4 weeks, and MMA and DMA remained stable up to 4.5 months. The same phenomenon was observed for 100 μg/liter mixed aqueous standards. There was no significant loss of arsenic species in urine (<5%) when passed through a 0.45-μm filter. The amounts of insoluble arsenic in urine lost during centrifuge ranged from 1/2 to 1/17 of soluble arsenic. These findings indicated that the urinary matrix plays an important role in stabilizing arsenic species. Also, the loss of insoluble arsenic in urine during centrifuging results in underestimation of arsenic exposure, and may explain the lack of an association between arsenic exposure and the risk ofhealth outcomes reported in some epidemiological studies.

UR - http://www.scopus.com/inward/record.url?scp=0036845682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036845682&partnerID=8YFLogxK

M3 - Article

C2 - 12433722

AN - SCOPUS:0036845682

VL - 11

SP - 1427

EP - 1433

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -